Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
2019年8月6日 - 10:00PM
Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage
biopharmaceutical company, announced today that Raj Mehra, PhD,
Chairman, Founder, and CEO of Seelos will ring the Nasdaq Stock
Market opening bell on Monday, August 12th at 9:30
am E.T., at the Nasdaq MarketSite in Times Square. The
ceremony may be viewed live via The MarketSite Webcam using:
https://new.livestream.com/nasdaq/live .
Seelos will also host meetings on August 12th after the Nasdaq
Opening Bell Ceremony at the BTIG Biotechnology Conference being
held at the St. Regis Hotel in New York, NY.
Dr. Mehra will be joined by the Seelos team to celebrate the IND
submission for the phase IIb/III clinical trial of SLS-005
(trehalose) for Sanfilippo Syndrome A and B patients and the
expanded access program for all Sanfilippo subtypes.
Additionally, Seelos is looking forward to initiating the
randomized placebo-controlled PK/PD study for SLS-002 (intranasal
ketamine targeting Suicidality in depression) along with the DDI
study in healthy volunteers.
Since listing publicly on the Nasdaq Stock Market, Seelos has
also acquired 2 Parkinson’s Disease programs targeting the
alpha-synuclein protein; SLS-007 which is a peptidic inhibitor
program and SLS-004 which is a gene therapy program targeting the
SNCA gene.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
disorders. The Company's robust portfolio includes several
late-stage clinical assets targeting psychiatric and movement
disorders, including orphan diseases. Seelos is based in New York,
New York. For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-looking Statements:
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include statements about the further development of SLS-002. Risks
and uncertainties include risks associated with development of
novel therapeutic programs generally, intellectual property and
regulatory risks related to the development of SLS-002 and
additional risks set forth in the Company's filings with the
Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (NASDAQ: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 9 2024 まで 10 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 10 2023 まで 10 2024